nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP1A2—Clobetasol propionate—psoriasis	0.0734	0.121	CbGbCtD
Etoricoxib—PTGS2—Triamcinolone—psoriasis	0.0587	0.0964	CbGbCtD
Etoricoxib—PTGS2—Betamethasone—psoriasis	0.0504	0.0827	CbGbCtD
Etoricoxib—CYP1A2—Methoxsalen—psoriasis	0.0386	0.0633	CbGbCtD
Etoricoxib—CYP2D6—Hydroxyurea—psoriasis	0.0348	0.057	CbGbCtD
Etoricoxib—PTGS2—Dexamethasone—psoriasis	0.0293	0.0481	CbGbCtD
Etoricoxib—CYP2C19—Cholecalciferol—psoriasis	0.0277	0.0455	CbGbCtD
Etoricoxib—CYP3A4—Calcitriol—psoriasis	0.026	0.0427	CbGbCtD
Etoricoxib—CYP2C9—Cholecalciferol—psoriasis	0.023	0.0378	CbGbCtD
Etoricoxib—CYP2D6—Cholecalciferol—psoriasis	0.0211	0.0346	CbGbCtD
Etoricoxib—CYP3A4—Methoxsalen—psoriasis	0.0202	0.0332	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—psoriasis	0.0192	0.0315	CbGbCtD
Etoricoxib—CYP2E1—Dexamethasone—psoriasis	0.0191	0.0314	CbGbCtD
Etoricoxib—CYP2C19—Cyclosporine—psoriasis	0.0182	0.0299	CbGbCtD
Etoricoxib—CYP2C9—Cyclosporine—psoriasis	0.0151	0.0248	CbGbCtD
Etoricoxib—CYP2D6—Cyclosporine—psoriasis	0.0138	0.0227	CbGbCtD
Etoricoxib—CYP3A4—Cholecalciferol—psoriasis	0.0134	0.022	CbGbCtD
Etoricoxib—CYP2C19—Dexamethasone—psoriasis	0.012	0.0197	CbGbCtD
Etoricoxib—CYP3A4—Mycophenolate mofetil—psoriasis	0.0116	0.0191	CbGbCtD
Etoricoxib—CYP3A4—Triamcinolone—psoriasis	0.0116	0.0191	CbGbCtD
Etoricoxib—CYP2C9—Dexamethasone—psoriasis	0.00996	0.0164	CbGbCtD
Etoricoxib—CYP3A4—Betamethasone—psoriasis	0.00996	0.0163	CbGbCtD
Etoricoxib—CYP3A4—Prednisolone—psoriasis	0.00983	0.0161	CbGbCtD
Etoricoxib—CYP3A4—Hydrocortisone—psoriasis	0.00932	0.0153	CbGbCtD
Etoricoxib—CYP3A4—Prednisone—psoriasis	0.00928	0.0152	CbGbCtD
Etoricoxib—CYP2D6—Dexamethasone—psoriasis	0.00911	0.015	CbGbCtD
Etoricoxib—CYP3A4—Cyclosporine—psoriasis	0.0088	0.0144	CbGbCtD
Etoricoxib—CYP3A4—Dexamethasone—psoriasis	0.00579	0.00951	CbGbCtD
Etoricoxib—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000876	0.157	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000702	0.126	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000682	0.122	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000529	0.0949	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000424	0.076	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000424	0.076	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000412	0.0738	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.00032	0.0574	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.00032	0.0574	CbGdCrCtD
Etoricoxib—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000313	0.0561	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000193	0.0346	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000193	0.0346	CbGdCrCtD
Etoricoxib—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000189	0.0338	CbGdCrCtD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—JUN—psoriasis	0.000124	0.00107	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—NFKB1—psoriasis	0.000122	0.00105	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88-independent cascade—JUN—psoriasis	0.000122	0.00105	CbGpPWpGaD
Etoricoxib—MAPK14—p53 pathway—TP53—psoriasis	0.000122	0.00105	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—ITGAL—psoriasis	0.000121	0.00105	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	0.00012	0.00104	CbGpPWpGaD
Etoricoxib—MAPK14—B Cell Receptor Signaling Pathway—NFKB1—psoriasis	0.000119	0.00103	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—JUN—psoriasis	0.000119	0.00103	CbGpPWpGaD
Etoricoxib—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000118	0.00102	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88-independent cascade—NFKB1—psoriasis	0.000117	0.00101	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—JUN—psoriasis	0.000116	0.001	CbGpPWpGaD
Etoricoxib—MAPK14—MAP kinase activation in TLR cascade—IL6—psoriasis	0.000116	0.001	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—CAT—psoriasis	0.000116	0.000999	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	0.000114	0.000988	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CARM1—psoriasis	0.000114	0.000984	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—TYK2—psoriasis	0.000113	0.000979	CbGpPWpGaD
Etoricoxib—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	0.000113	0.000977	CbGpPWpGaD
Etoricoxib—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000113	0.000972	CbGpPWpGaD
Etoricoxib—MAPK14—Oncostatin M Signaling Pathway—TP53—psoriasis	0.000113	0.000971	CbGpPWpGaD
Etoricoxib—MAPK14—ATF-2 transcription factor network—IL6—psoriasis	0.000111	0.000961	CbGpPWpGaD
Etoricoxib—MAPK14—Rac1/Pak1/p38/MMP-2 pathway—TP53—psoriasis	0.00011	0.000948	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—JUN—psoriasis	0.00011	0.000946	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—LEP—psoriasis	0.000109	0.000944	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000109	0.000937	CbGpPWpGaD
Etoricoxib—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000108	0.000928	CbGpPWpGaD
Etoricoxib—MAPK14—Activated TLR4 signalling—NFKB1—psoriasis	0.000105	0.00091	CbGpPWpGaD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—JUN—psoriasis	0.000105	0.000907	CbGpPWpGaD
Etoricoxib—MAPK14—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	0.000104	0.000898	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—JUN—psoriasis	0.000103	0.000889	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	0.000103	0.000887	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—NOS2—psoriasis	0.000102	0.00088	CbGpPWpGaD
Etoricoxib—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.000101	0.000868	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	0.0001	0.000863	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	9.99e-05	0.000862	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IFIH1—psoriasis	9.93e-05	0.000856	CbGpPWpGaD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	9.92e-05	0.000856	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—CD4—psoriasis	9.92e-05	0.000856	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	9.89e-05	0.000854	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—JUN—psoriasis	9.68e-05	0.000835	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ERAP1—psoriasis	9.54e-05	0.000823	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—VEGFA—psoriasis	9.44e-05	0.000815	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HLA-C—psoriasis	9.41e-05	0.000812	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	9.41e-05	0.000812	CbGpPWpGaD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—TP53—psoriasis	9.35e-05	0.000807	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—TNFAIP3—psoriasis	9.29e-05	0.000802	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—JUN—psoriasis	9.29e-05	0.000801	CbGpPWpGaD
Etoricoxib—MAPK14—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	9.19e-05	0.000793	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—JUN—psoriasis	9.18e-05	0.000792	CbGpPWpGaD
Etoricoxib—Diarrhoea—Mycophenolic acid—psoriasis	9.1e-05	0.000338	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—psoriasis	9.09e-05	0.000338	CcSEcCtD
Etoricoxib—Angiopathy—Prednisone—psoriasis	9.09e-05	0.000338	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—psoriasis	9.06e-05	0.000337	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	9.06e-05	0.000337	CcSEcCtD
Etoricoxib—Immune system disorder—Prednisone—psoriasis	9.05e-05	0.000336	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—JUN—psoriasis	9.03e-05	0.000779	CbGpPWpGaD
Etoricoxib—Anaphylactic shock—Triamcinolone—psoriasis	9.01e-05	0.000335	CcSEcCtD
Etoricoxib—Oedema—Triamcinolone—psoriasis	9.01e-05	0.000335	CcSEcCtD
Etoricoxib—Pain—Mycophenolate mofetil—psoriasis	8.98e-05	0.000333	CcSEcCtD
Etoricoxib—Constipation—Mycophenolate mofetil—psoriasis	8.98e-05	0.000333	CcSEcCtD
Etoricoxib—Arrhythmia—Prednisone—psoriasis	8.95e-05	0.000332	CcSEcCtD
Etoricoxib—Infection—Triamcinolone—psoriasis	8.95e-05	0.000332	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	8.94e-05	0.000771	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—TNF—psoriasis	8.91e-05	0.000768	CbGpPWpGaD
Etoricoxib—Haematuria—Methotrexate—psoriasis	8.89e-05	0.00033	CcSEcCtD
Etoricoxib—Feeling abnormal—Cyclosporine—psoriasis	8.87e-05	0.000329	CcSEcCtD
Etoricoxib—Shock—Triamcinolone—psoriasis	8.86e-05	0.000329	CcSEcCtD
Etoricoxib—Insomnia—Prednisolone—psoriasis	8.86e-05	0.000329	CcSEcCtD
Etoricoxib—Alopecia—Prednisone—psoriasis	8.85e-05	0.000329	CcSEcCtD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—NFKB1—psoriasis	8.84e-05	0.000762	CbGpPWpGaD
Etoricoxib—Hepatobiliary disease—Methotrexate—psoriasis	8.82e-05	0.000328	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Cyclosporine—psoriasis	8.8e-05	0.000327	CcSEcCtD
Etoricoxib—Dizziness—Mycophenolic acid—psoriasis	8.8e-05	0.000327	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—psoriasis	8.8e-05	0.000327	CcSEcCtD
Etoricoxib—Mental disorder—Prednisone—psoriasis	8.78e-05	0.000326	CcSEcCtD
Etoricoxib—Malnutrition—Prednisone—psoriasis	8.72e-05	0.000324	CcSEcCtD
Etoricoxib—Erythema—Prednisone—psoriasis	8.72e-05	0.000324	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	8.71e-05	0.000324	CcSEcCtD
Etoricoxib—MAPK14—BDNF signaling pathway—NFKB1—psoriasis	8.69e-05	0.00075	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Mycophenolate mofetil—psoriasis	8.65e-05	0.000321	CcSEcCtD
Etoricoxib—Insomnia—Hydrocortisone—psoriasis	8.65e-05	0.000321	CcSEcCtD
Etoricoxib—Hypertension—Dexamethasone—psoriasis	8.64e-05	0.000321	CcSEcCtD
Etoricoxib—Hypertension—Betamethasone—psoriasis	8.64e-05	0.000321	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—HCAR2—psoriasis	8.59e-05	0.000741	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	8.59e-05	0.000319	CcSEcCtD
Etoricoxib—MAPK14—Glucocorticoid receptor regulatory network—IL6—psoriasis	8.56e-05	0.000738	CbGpPWpGaD
Etoricoxib—Urticaria—Cyclosporine—psoriasis	8.55e-05	0.000318	CcSEcCtD
Etoricoxib—Abdominal pain—Cyclosporine—psoriasis	8.51e-05	0.000316	CcSEcCtD
Etoricoxib—Anxiety—Betamethasone—psoriasis	8.5e-05	0.000316	CcSEcCtD
Etoricoxib—Anxiety—Dexamethasone—psoriasis	8.5e-05	0.000316	CcSEcCtD
Etoricoxib—Vomiting—Mycophenolic acid—psoriasis	8.46e-05	0.000314	CcSEcCtD
Etoricoxib—Dyspepsia—Hydrocortisone—psoriasis	8.42e-05	0.000313	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—psoriasis	8.41e-05	0.000313	CcSEcCtD
Etoricoxib—MAPK14—Immune System—DDX58—psoriasis	8.4e-05	0.000725	CbGpPWpGaD
Etoricoxib—Rash—Mycophenolic acid—psoriasis	8.39e-05	0.000312	CcSEcCtD
Etoricoxib—Dermatitis—Mycophenolic acid—psoriasis	8.38e-05	0.000311	CcSEcCtD
Etoricoxib—Pain—Prednisolone—psoriasis	8.37e-05	0.000311	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	8.37e-05	0.000723	CbGpPWpGaD
Etoricoxib—Hepatitis—Methotrexate—psoriasis	8.37e-05	0.000311	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—psoriasis	8.37e-05	0.000311	CcSEcCtD
Etoricoxib—Urticaria—Mycophenolate mofetil—psoriasis	8.34e-05	0.00031	CcSEcCtD
Etoricoxib—Headache—Mycophenolic acid—psoriasis	8.33e-05	0.00031	CcSEcCtD
Etoricoxib—MAPK14—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	8.32e-05	0.000717	CbGpPWpGaD
Etoricoxib—Decreased appetite—Hydrocortisone—psoriasis	8.31e-05	0.000309	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—psoriasis	8.31e-05	0.000309	CcSEcCtD
Etoricoxib—Abdominal pain—Mycophenolate mofetil—psoriasis	8.3e-05	0.000308	CcSEcCtD
Etoricoxib—MAPK14—Insulin Signaling—JUN—psoriasis	8.3e-05	0.000716	CbGpPWpGaD
Etoricoxib—Urinary tract disorder—Methotrexate—psoriasis	8.27e-05	0.000307	CcSEcCtD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	8.26e-05	0.000713	CbGpPWpGaD
Etoricoxib—Gastrointestinal disorder—Hydrocortisone—psoriasis	8.26e-05	0.000307	CcSEcCtD
Etoricoxib—Fatigue—Hydrocortisone—psoriasis	8.25e-05	0.000306	CcSEcCtD
Etoricoxib—MAPK14—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	8.24e-05	0.000711	CbGpPWpGaD
Etoricoxib—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	8.23e-05	0.00071	CbGpPWpGaD
Etoricoxib—Vision blurred—Prednisone—psoriasis	8.22e-05	0.000305	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—JUN—psoriasis	8.21e-05	0.000709	CbGpPWpGaD
Etoricoxib—Urethral disorder—Methotrexate—psoriasis	8.21e-05	0.000305	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Triamcinolone—psoriasis	8.21e-05	0.000305	CcSEcCtD
Etoricoxib—Pain—Hydrocortisone—psoriasis	8.18e-05	0.000304	CcSEcCtD
Etoricoxib—Anaphylactic shock—Dexamethasone—psoriasis	8.17e-05	0.000304	CcSEcCtD
Etoricoxib—Oedema—Dexamethasone—psoriasis	8.17e-05	0.000304	CcSEcCtD
Etoricoxib—Oedema—Betamethasone—psoriasis	8.17e-05	0.000304	CcSEcCtD
Etoricoxib—Anaphylactic shock—Betamethasone—psoriasis	8.17e-05	0.000304	CcSEcCtD
Etoricoxib—Insomnia—Triamcinolone—psoriasis	8.15e-05	0.000303	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	8.13e-05	0.000702	CbGpPWpGaD
Etoricoxib—Infection—Dexamethasone—psoriasis	8.12e-05	0.000302	CcSEcCtD
Etoricoxib—Infection—Betamethasone—psoriasis	8.12e-05	0.000302	CcSEcCtD
Etoricoxib—MAPK14—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	8.09e-05	0.000698	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Prednisolone—psoriasis	8.07e-05	0.0003	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—psoriasis	8.07e-05	0.0003	CcSEcCtD
Etoricoxib—Anaemia—Prednisone—psoriasis	8.06e-05	0.000299	CcSEcCtD
Etoricoxib—Shock—Betamethasone—psoriasis	8.04e-05	0.000299	CcSEcCtD
Etoricoxib—Shock—Dexamethasone—psoriasis	8.04e-05	0.000299	CcSEcCtD
Etoricoxib—Dyspnoea—Triamcinolone—psoriasis	8.03e-05	0.000298	CcSEcCtD
Etoricoxib—Nervous system disorder—Betamethasone—psoriasis	8.01e-05	0.000298	CcSEcCtD
Etoricoxib—Nervous system disorder—Dexamethasone—psoriasis	8.01e-05	0.000298	CcSEcCtD
Etoricoxib—Agitation—Prednisone—psoriasis	8.01e-05	0.000298	CcSEcCtD
Etoricoxib—Thrombocytopenia—Betamethasone—psoriasis	8e-05	0.000297	CcSEcCtD
Etoricoxib—Thrombocytopenia—Dexamethasone—psoriasis	8e-05	0.000297	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—JUN—psoriasis	7.98e-05	0.000689	CbGpPWpGaD
Etoricoxib—Angioedema—Prednisone—psoriasis	7.97e-05	0.000296	CcSEcCtD
Etoricoxib—MAPK14—TCR Signaling Pathway—IL6—psoriasis	7.94e-05	0.000685	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Cyclosporine—psoriasis	7.93e-05	0.000295	CcSEcCtD
Etoricoxib—Dyspepsia—Triamcinolone—psoriasis	7.93e-05	0.000294	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—psoriasis	7.92e-05	0.000294	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—CXCL8—psoriasis	7.91e-05	0.000683	CbGpPWpGaD
Etoricoxib—Nausea—Mycophenolic acid—psoriasis	7.9e-05	0.000294	CcSEcCtD
Etoricoxib—Feeling abnormal—Hydrocortisone—psoriasis	7.88e-05	0.000293	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—NFKBIA—psoriasis	7.86e-05	0.000679	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	7.83e-05	0.000675	CbGpPWpGaD
Etoricoxib—Eye disorder—Methotrexate—psoriasis	7.82e-05	0.000291	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—IFNG—psoriasis	7.82e-05	0.000675	CbGpPWpGaD
Etoricoxib—Gastrointestinal pain—Hydrocortisone—psoriasis	7.82e-05	0.000291	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—HLA-E—psoriasis	7.81e-05	0.000674	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—STAT3—psoriasis	7.81e-05	0.000674	CbGpPWpGaD
Etoricoxib—Tinnitus—Methotrexate—psoriasis	7.81e-05	0.00029	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	7.81e-05	0.000673	CbGpPWpGaD
Etoricoxib—Anorexia—Dexamethasone—psoriasis	7.79e-05	0.000289	CcSEcCtD
Etoricoxib—Anorexia—Betamethasone—psoriasis	7.79e-05	0.000289	CcSEcCtD
Etoricoxib—Urticaria—Prednisolone—psoriasis	7.78e-05	0.000289	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—psoriasis	7.77e-05	0.000289	CcSEcCtD
Etoricoxib—Fatigue—Triamcinolone—psoriasis	7.76e-05	0.000288	CcSEcCtD
Etoricoxib—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.74e-05	0.000287	CcSEcCtD
Etoricoxib—Asthenia—Cyclosporine—psoriasis	7.72e-05	0.000287	CcSEcCtD
Etoricoxib—Pain—Triamcinolone—psoriasis	7.7e-05	0.000286	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—NFKB1—psoriasis	7.68e-05	0.000663	CbGpPWpGaD
Etoricoxib—MAPK14—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	7.67e-05	0.000662	CbGpPWpGaD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—TP53—psoriasis	7.67e-05	0.000662	CbGpPWpGaD
Etoricoxib—Pruritus—Cyclosporine—psoriasis	7.61e-05	0.000283	CcSEcCtD
Etoricoxib—Urticaria—Hydrocortisone—psoriasis	7.6e-05	0.000282	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—psoriasis	7.6e-05	0.000282	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—psoriasis	7.56e-05	0.000281	CcSEcCtD
Etoricoxib—Abdominal pain—Hydrocortisone—psoriasis	7.56e-05	0.000281	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—psoriasis	7.54e-05	0.00028	CcSEcCtD
Etoricoxib—Asthenia—Mycophenolate mofetil—psoriasis	7.53e-05	0.00028	CcSEcCtD
Etoricoxib—Hypertension—Prednisone—psoriasis	7.53e-05	0.00028	CcSEcCtD
Etoricoxib—MAPK14—Signaling Pathways—TAGAP—psoriasis	7.45e-05	0.000642	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Dexamethasone—psoriasis	7.45e-05	0.000277	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Betamethasone—psoriasis	7.45e-05	0.000277	CcSEcCtD
Etoricoxib—Pruritus—Mycophenolate mofetil—psoriasis	7.43e-05	0.000276	CcSEcCtD
Etoricoxib—Arthralgia—Prednisone—psoriasis	7.42e-05	0.000276	CcSEcCtD
Etoricoxib—Feeling abnormal—Triamcinolone—psoriasis	7.42e-05	0.000276	CcSEcCtD
Etoricoxib—Anxiety—Prednisone—psoriasis	7.4e-05	0.000275	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—psoriasis	7.4e-05	0.000275	CcSEcCtD
Etoricoxib—Insomnia—Dexamethasone—psoriasis	7.39e-05	0.000275	CcSEcCtD
Etoricoxib—Insomnia—Betamethasone—psoriasis	7.39e-05	0.000275	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	7.37e-05	0.000274	CcSEcCtD
Etoricoxib—Diarrhoea—Cyclosporine—psoriasis	7.36e-05	0.000274	CcSEcCtD
Etoricoxib—MAPK14—MyD88-independent cascade—IL6—psoriasis	7.36e-05	0.000635	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—JUN—psoriasis	7.36e-05	0.000635	CbGpPWpGaD
Etoricoxib—Mental disorder—Methotrexate—psoriasis	7.33e-05	0.000272	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—psoriasis	7.29e-05	0.000271	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—psoriasis	7.29e-05	0.000271	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	7.27e-05	0.000628	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Prednisolone—psoriasis	7.22e-05	0.000268	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.2e-05	0.000621	CbGpPWpGaD
Etoricoxib—Dyspepsia—Dexamethasone—psoriasis	7.19e-05	0.000267	CcSEcCtD
Etoricoxib—Dyspepsia—Betamethasone—psoriasis	7.19e-05	0.000267	CcSEcCtD
Etoricoxib—MAPK14—Toll-like Receptor Signaling Pathway—IL6—psoriasis	7.19e-05	0.00062	CbGpPWpGaD
Etoricoxib—Diarrhoea—Mycophenolate mofetil—psoriasis	7.18e-05	0.000267	CcSEcCtD
Etoricoxib—Urticaria—Triamcinolone—psoriasis	7.15e-05	0.000266	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—psoriasis	7.14e-05	0.000265	CcSEcCtD
Etoricoxib—Dizziness—Cyclosporine—psoriasis	7.12e-05	0.000264	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—psoriasis	7.12e-05	0.000264	CcSEcCtD
Etoricoxib—Oedema—Prednisone—psoriasis	7.12e-05	0.000264	CcSEcCtD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—STAT3—psoriasis	7.11e-05	0.000613	CbGpPWpGaD
Etoricoxib—Decreased appetite—Dexamethasone—psoriasis	7.1e-05	0.000264	CcSEcCtD
Etoricoxib—Decreased appetite—Betamethasone—psoriasis	7.1e-05	0.000264	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	7.1e-05	0.000613	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—NFKB1—psoriasis	7.08e-05	0.000611	CbGpPWpGaD
Etoricoxib—Infection—Prednisone—psoriasis	7.07e-05	0.000263	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Dexamethasone—psoriasis	7.06e-05	0.000262	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Betamethasone—psoriasis	7.06e-05	0.000262	CcSEcCtD
Etoricoxib—Hypersensitivity—Hydrocortisone—psoriasis	7.05e-05	0.000262	CcSEcCtD
Etoricoxib—Fatigue—Betamethasone—psoriasis	7.05e-05	0.000262	CcSEcCtD
Etoricoxib—Fatigue—Dexamethasone—psoriasis	7.05e-05	0.000262	CcSEcCtD
Etoricoxib—MAPK14—Senescence and Autophagy in Cancer—IL6—psoriasis	7.02e-05	0.000606	CbGpPWpGaD
Etoricoxib—Shock—Prednisone—psoriasis	7e-05	0.00026	CcSEcCtD
Etoricoxib—Pain—Dexamethasone—psoriasis	6.99e-05	0.00026	CcSEcCtD
Etoricoxib—Pain—Betamethasone—psoriasis	6.99e-05	0.00026	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—psoriasis	6.98e-05	0.000259	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—NDUFA5—psoriasis	6.98e-05	0.000602	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	6.95e-05	0.0006	CbGpPWpGaD
Etoricoxib—Dizziness—Mycophenolate mofetil—psoriasis	6.94e-05	0.000258	CcSEcCtD
Etoricoxib—MAPK14—Oxidative Stress Induced Senescence—TP53—psoriasis	6.94e-05	0.000599	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.94e-05	0.000599	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.93e-05	0.000598	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—IL6—psoriasis	6.92e-05	0.000597	CbGpPWpGaD
Etoricoxib—Skin disorder—Prednisone—psoriasis	6.91e-05	0.000257	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—psoriasis	6.87e-05	0.000255	CcSEcCtD
Etoricoxib—Asthenia—Hydrocortisone—psoriasis	6.86e-05	0.000255	CcSEcCtD
Etoricoxib—Vomiting—Cyclosporine—psoriasis	6.84e-05	0.000254	CcSEcCtD
Etoricoxib—Rash—Cyclosporine—psoriasis	6.79e-05	0.000252	CcSEcCtD
Etoricoxib—Anorexia—Prednisone—psoriasis	6.78e-05	0.000252	CcSEcCtD
Etoricoxib—Dermatitis—Cyclosporine—psoriasis	6.78e-05	0.000252	CcSEcCtD
Etoricoxib—Pruritus—Hydrocortisone—psoriasis	6.77e-05	0.000251	CcSEcCtD
Etoricoxib—Headache—Cyclosporine—psoriasis	6.74e-05	0.00025	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—psoriasis	6.74e-05	0.00025	CcSEcCtD
Etoricoxib—Feeling abnormal—Dexamethasone—psoriasis	6.73e-05	0.00025	CcSEcCtD
Etoricoxib—Feeling abnormal—Betamethasone—psoriasis	6.73e-05	0.00025	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Dexamethasone—psoriasis	6.68e-05	0.000248	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Betamethasone—psoriasis	6.68e-05	0.000248	CcSEcCtD
Etoricoxib—Vomiting—Mycophenolate mofetil—psoriasis	6.68e-05	0.000248	CcSEcCtD
Etoricoxib—Hypersensitivity—Triamcinolone—psoriasis	6.64e-05	0.000246	CcSEcCtD
Etoricoxib—MAPK14—Activated TLR4 signalling—IL6—psoriasis	6.62e-05	0.000571	CbGpPWpGaD
Etoricoxib—Rash—Mycophenolate mofetil—psoriasis	6.62e-05	0.000246	CcSEcCtD
Etoricoxib—Dermatitis—Mycophenolate mofetil—psoriasis	6.61e-05	0.000246	CcSEcCtD
Etoricoxib—Headache—Mycophenolate mofetil—psoriasis	6.58e-05	0.000244	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—NDUFA5—psoriasis	6.57e-05	0.000567	CbGpPWpGaD
Etoricoxib—Diarrhoea—Hydrocortisone—psoriasis	6.54e-05	0.000243	CcSEcCtD
Etoricoxib—MAPK14—Signaling by VEGF—IL6—psoriasis	6.53e-05	0.000563	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—SOCS1—psoriasis	6.52e-05	0.000563	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.51e-05	0.000561	CbGpPWpGaD
Etoricoxib—Urticaria—Betamethasone—psoriasis	6.49e-05	0.000241	CcSEcCtD
Etoricoxib—Urticaria—Dexamethasone—psoriasis	6.49e-05	0.000241	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—psoriasis	6.48e-05	0.000241	CcSEcCtD
Etoricoxib—Dizziness—Prednisolone—psoriasis	6.48e-05	0.000241	CcSEcCtD
Etoricoxib—Asthenia—Triamcinolone—psoriasis	6.46e-05	0.00024	CcSEcCtD
Etoricoxib—Abdominal pain—Betamethasone—psoriasis	6.46e-05	0.00024	CcSEcCtD
Etoricoxib—Abdominal pain—Dexamethasone—psoriasis	6.46e-05	0.00024	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—TYK2—psoriasis	6.44e-05	0.000556	CbGpPWpGaD
Etoricoxib—Insomnia—Prednisone—psoriasis	6.44e-05	0.000239	CcSEcCtD
Etoricoxib—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	6.4e-05	0.000552	CbGpPWpGaD
Etoricoxib—Nausea—Cyclosporine—psoriasis	6.39e-05	0.000237	CcSEcCtD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TP53—psoriasis	6.39e-05	0.000551	CbGpPWpGaD
Etoricoxib—Pruritus—Triamcinolone—psoriasis	6.37e-05	0.000237	CcSEcCtD
Etoricoxib—MAPK14—Immune System—ITGAL—psoriasis	6.37e-05	0.000549	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—STAT3—psoriasis	6.36e-05	0.000549	CbGpPWpGaD
Etoricoxib—Cough—Methotrexate—psoriasis	6.36e-05	0.000236	CcSEcCtD
Etoricoxib—Dizziness—Hydrocortisone—psoriasis	6.33e-05	0.000235	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.29e-05	0.000543	CbGpPWpGaD
Etoricoxib—Dyspepsia—Prednisone—psoriasis	6.26e-05	0.000233	CcSEcCtD
Etoricoxib—Nausea—Mycophenolate mofetil—psoriasis	6.24e-05	0.000232	CcSEcCtD
Etoricoxib—MAPK14—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	6.23e-05	0.000537	CbGpPWpGaD
Etoricoxib—Chest pain—Methotrexate—psoriasis	6.2e-05	0.00023	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—psoriasis	6.2e-05	0.00023	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—psoriasis	6.19e-05	0.00023	CcSEcCtD
Etoricoxib—Rash—Prednisolone—psoriasis	6.17e-05	0.000229	CcSEcCtD
Etoricoxib—Dermatitis—Prednisolone—psoriasis	6.17e-05	0.000229	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.16e-05	0.000229	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—psoriasis	6.14e-05	0.000228	CcSEcCtD
Etoricoxib—Headache—Prednisolone—psoriasis	6.14e-05	0.000228	CcSEcCtD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.09e-05	0.000525	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.09e-05	0.000525	CbGpPWpGaD
Etoricoxib—Constipation—Prednisone—psoriasis	6.09e-05	0.000226	CcSEcCtD
Etoricoxib—Vomiting—Hydrocortisone—psoriasis	6.08e-05	0.000226	CcSEcCtD
Etoricoxib—Rash—Hydrocortisone—psoriasis	6.03e-05	0.000224	CcSEcCtD
Etoricoxib—Dermatitis—Hydrocortisone—psoriasis	6.03e-05	0.000224	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—psoriasis	6e-05	0.000223	CcSEcCtD
Etoricoxib—Headache—Hydrocortisone—psoriasis	5.99e-05	0.000223	CcSEcCtD
Etoricoxib—MAPK14—Cellular responses to stress—CXCL8—psoriasis	5.98e-05	0.000516	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TNF—psoriasis	5.97e-05	0.000516	CbGpPWpGaD
Etoricoxib—Dizziness—Triamcinolone—psoriasis	5.96e-05	0.000221	CcSEcCtD
Etoricoxib—MAPK14—Immune System—REL—psoriasis	5.96e-05	0.000514	CbGpPWpGaD
Etoricoxib—Anaphylactic shock—Methotrexate—psoriasis	5.95e-05	0.000221	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—CYP2S1—psoriasis	5.93e-05	0.000512	CbGpPWpGaD
Etoricoxib—Infection—Methotrexate—psoriasis	5.91e-05	0.000219	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisone—psoriasis	5.86e-05	0.000218	CcSEcCtD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	5.86e-05	0.000506	CbGpPWpGaD
Etoricoxib—Asthenia—Betamethasone—psoriasis	5.86e-05	0.000218	CcSEcCtD
Etoricoxib—Asthenia—Dexamethasone—psoriasis	5.86e-05	0.000218	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—CARM1—psoriasis	5.83e-05	0.000503	CbGpPWpGaD
Etoricoxib—Nervous system disorder—Methotrexate—psoriasis	5.83e-05	0.000217	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—psoriasis	5.82e-05	0.000216	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—psoriasis	5.82e-05	0.000216	CcSEcCtD
Etoricoxib—Nausea—Prednisolone—psoriasis	5.82e-05	0.000216	CcSEcCtD
Etoricoxib—Pruritus—Dexamethasone—psoriasis	5.78e-05	0.000215	CcSEcCtD
Etoricoxib—Pruritus—Betamethasone—psoriasis	5.78e-05	0.000215	CcSEcCtD
Etoricoxib—MAPK14—Immune System—IFIH1—psoriasis	5.78e-05	0.000499	CbGpPWpGaD
Etoricoxib—Skin disorder—Methotrexate—psoriasis	5.78e-05	0.000215	CcSEcCtD
Etoricoxib—Vomiting—Triamcinolone—psoriasis	5.73e-05	0.000213	CcSEcCtD
Etoricoxib—Nausea—Hydrocortisone—psoriasis	5.68e-05	0.000211	CcSEcCtD
Etoricoxib—Rash—Triamcinolone—psoriasis	5.68e-05	0.000211	CcSEcCtD
Etoricoxib—Dermatitis—Triamcinolone—psoriasis	5.67e-05	0.000211	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—psoriasis	5.67e-05	0.000211	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—psoriasis	5.65e-05	0.00021	CcSEcCtD
Etoricoxib—Headache—Triamcinolone—psoriasis	5.64e-05	0.00021	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—psoriasis	5.63e-05	0.000209	CcSEcCtD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	5.61e-05	0.000484	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—psoriasis	5.6e-05	0.000483	CbGpPWpGaD
Etoricoxib—Diarrhoea—Dexamethasone—psoriasis	5.59e-05	0.000208	CcSEcCtD
Etoricoxib—Diarrhoea—Betamethasone—psoriasis	5.59e-05	0.000208	CcSEcCtD
Etoricoxib—CYP2E1—Metabolism—CYP2S1—psoriasis	5.59e-05	0.000482	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HLA-B—psoriasis	5.56e-05	0.00048	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—JUN—psoriasis	5.56e-05	0.00048	CbGpPWpGaD
Etoricoxib—MAPK14—Toll-Like Receptors Cascades—IL6—psoriasis	5.55e-05	0.000479	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-C—psoriasis	5.48e-05	0.000473	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—LEP—psoriasis	5.45e-05	0.00047	CbGpPWpGaD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—psoriasis	5.42e-05	0.000201	CcSEcCtD
Etoricoxib—MAPK14—Immune System—TNFAIP3—psoriasis	5.41e-05	0.000467	CbGpPWpGaD
Etoricoxib—Dizziness—Betamethasone—psoriasis	5.4e-05	0.000201	CcSEcCtD
Etoricoxib—Dizziness—Dexamethasone—psoriasis	5.4e-05	0.000201	CcSEcCtD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.39e-05	0.000465	CbGpPWpGaD
Etoricoxib—Insomnia—Methotrexate—psoriasis	5.38e-05	0.0002	CcSEcCtD
Etoricoxib—MAPK14—Cellular responses to stress—NFKB1—psoriasis	5.35e-05	0.000462	CbGpPWpGaD
Etoricoxib—Nausea—Triamcinolone—psoriasis	5.35e-05	0.000199	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—psoriasis	5.3e-05	0.000197	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—psoriasis	5.29e-05	0.000196	CcSEcCtD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TP53—psoriasis	5.27e-05	0.000454	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Prednisone—psoriasis	5.24e-05	0.000195	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—psoriasis	5.24e-05	0.000194	CcSEcCtD
Etoricoxib—Vomiting—Betamethasone—psoriasis	5.2e-05	0.000193	CcSEcCtD
Etoricoxib—Vomiting—Dexamethasone—psoriasis	5.2e-05	0.000193	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—psoriasis	5.17e-05	0.000192	CcSEcCtD
Etoricoxib—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	5.17e-05	0.000446	CbGpPWpGaD
Etoricoxib—Rash—Betamethasone—psoriasis	5.15e-05	0.000191	CcSEcCtD
Etoricoxib—Rash—Dexamethasone—psoriasis	5.15e-05	0.000191	CcSEcCtD
Etoricoxib—Dermatitis—Betamethasone—psoriasis	5.15e-05	0.000191	CcSEcCtD
Etoricoxib—Dermatitis—Dexamethasone—psoriasis	5.15e-05	0.000191	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—psoriasis	5.13e-05	0.000191	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—psoriasis	5.13e-05	0.00019	CcSEcCtD
Etoricoxib—Headache—Dexamethasone—psoriasis	5.12e-05	0.00019	CcSEcCtD
Etoricoxib—Headache—Betamethasone—psoriasis	5.12e-05	0.00019	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—psoriasis	5.11e-05	0.00019	CcSEcCtD
Etoricoxib—Pain—Methotrexate—psoriasis	5.09e-05	0.000189	CcSEcCtD
Etoricoxib—CYP2C19—Metabolism—NDUFA5—psoriasis	5.07e-05	0.000437	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TNF—psoriasis	5.06e-05	0.000437	CbGpPWpGaD
Etoricoxib—Pruritus—Prednisone—psoriasis	5.03e-05	0.000187	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—NFKB1—psoriasis	5.02e-05	0.000433	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NOS2—psoriasis	4.98e-05	0.00043	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CRP—psoriasis	4.92e-05	0.000424	CbGpPWpGaD
Etoricoxib—Feeling abnormal—Methotrexate—psoriasis	4.9e-05	0.000182	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—psoriasis	4.87e-05	0.000181	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—psoriasis	4.86e-05	0.000181	CcSEcCtD
Etoricoxib—MAPK14—Cellular responses to stress—VEGFA—psoriasis	4.86e-05	0.000419	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—TP53—psoriasis	4.86e-05	0.000419	CbGpPWpGaD
Etoricoxib—Nausea—Dexamethasone—psoriasis	4.85e-05	0.00018	CcSEcCtD
Etoricoxib—Nausea—Betamethasone—psoriasis	4.85e-05	0.00018	CcSEcCtD
Etoricoxib—MAPK14—Cellular responses to stress—STAT3—psoriasis	4.81e-05	0.000415	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.75e-05	0.00041	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—PPARG—psoriasis	4.75e-05	0.00041	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.73e-05	0.000408	CbGpPWpGaD
Etoricoxib—Urticaria—Methotrexate—psoriasis	4.72e-05	0.000175	CcSEcCtD
Etoricoxib—Dizziness—Prednisone—psoriasis	4.71e-05	0.000175	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—psoriasis	4.7e-05	0.000175	CcSEcCtD
Etoricoxib—CYP2D6—Metabolism—NDUFA5—psoriasis	4.66e-05	0.000402	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NDUFA5—psoriasis	4.62e-05	0.000399	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.6e-05	0.000397	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-E—psoriasis	4.55e-05	0.000392	CbGpPWpGaD
Etoricoxib—Vomiting—Prednisone—psoriasis	4.52e-05	0.000168	CcSEcCtD
Etoricoxib—MAPK14—Signaling by NGF—STAT3—psoriasis	4.51e-05	0.000389	CbGpPWpGaD
Etoricoxib—Rash—Prednisone—psoriasis	4.49e-05	0.000167	CcSEcCtD
Etoricoxib—MAPK14—Innate Immune System—NFKBIA—psoriasis	4.49e-05	0.000387	CbGpPWpGaD
Etoricoxib—Dermatitis—Prednisone—psoriasis	4.48e-05	0.000167	CcSEcCtD
Etoricoxib—PTGS2—Spinal Cord Injury—TP53—psoriasis	4.46e-05	0.000385	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCL20—psoriasis	4.46e-05	0.000385	CbGpPWpGaD
Etoricoxib—Headache—Prednisone—psoriasis	4.46e-05	0.000166	CcSEcCtD
Etoricoxib—MAPK14—Cellular Senescence—IL6—psoriasis	4.44e-05	0.000383	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.43e-05	0.000382	CbGpPWpGaD
Etoricoxib—Hypersensitivity—Methotrexate—psoriasis	4.38e-05	0.000163	CcSEcCtD
Etoricoxib—CYP2C19—Metabolism—CYP2S1—psoriasis	4.31e-05	0.000372	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.31e-05	0.000372	CbGpPWpGaD
Etoricoxib—Asthenia—Methotrexate—psoriasis	4.27e-05	0.000159	CcSEcCtD
Etoricoxib—Nausea—Prednisone—psoriasis	4.23e-05	0.000157	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—psoriasis	4.21e-05	0.000156	CcSEcCtD
Etoricoxib—MAPK14—Developmental Biology—TYK2—psoriasis	4.16e-05	0.000359	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.1e-05	0.000353	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—IL6—psoriasis	4.09e-05	0.000353	CbGpPWpGaD
Etoricoxib—Diarrhoea—Methotrexate—psoriasis	4.07e-05	0.000151	CcSEcCtD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.02e-05	0.000347	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP2S1—psoriasis	3.96e-05	0.000342	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NDUFA5—psoriasis	3.95e-05	0.000341	CbGpPWpGaD
Etoricoxib—Dizziness—Methotrexate—psoriasis	3.93e-05	0.000146	CcSEcCtD
Etoricoxib—CYP2C9—Metabolism—CYP2S1—psoriasis	3.93e-05	0.000339	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—SOCS1—psoriasis	3.8e-05	0.000328	CbGpPWpGaD
Etoricoxib—Vomiting—Methotrexate—psoriasis	3.78e-05	0.00014	CcSEcCtD
Etoricoxib—Rash—Methotrexate—psoriasis	3.75e-05	0.000139	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—psoriasis	3.75e-05	0.000139	CcSEcCtD
Etoricoxib—Headache—Methotrexate—psoriasis	3.73e-05	0.000138	CcSEcCtD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.68e-05	0.000318	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—TYK2—psoriasis	3.67e-05	0.000317	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—TP53—psoriasis	3.67e-05	0.000317	CbGpPWpGaD
Etoricoxib—Nausea—Methotrexate—psoriasis	3.53e-05	0.000131	CcSEcCtD
Etoricoxib—MAPK14—Gene Expression—VDR—psoriasis	3.48e-05	0.000301	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.44e-05	0.000297	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD8A—psoriasis	3.37e-05	0.000291	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—IL6—psoriasis	3.36e-05	0.00029	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2S1—psoriasis	3.36e-05	0.00029	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CD4—psoriasis	3.32e-05	0.000287	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—NFKB1—psoriasis	3.24e-05	0.00028	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-B—psoriasis	3.24e-05	0.00028	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—IL6—psoriasis	3.15e-05	0.000272	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.11e-05	0.000268	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NDUFA5—psoriasis	3.05e-05	0.000263	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.04e-05	0.000262	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-A—psoriasis	3e-05	0.000259	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—JUN—psoriasis	2.97e-05	0.000257	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—VEGFA—psoriasis	2.94e-05	0.000254	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—STAT3—psoriasis	2.91e-05	0.000251	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CARM1—psoriasis	2.9e-05	0.00025	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—VEGFA—psoriasis	2.89e-05	0.000249	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CRP—psoriasis	2.86e-05	0.000247	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NFKB1—psoriasis	2.86e-05	0.000247	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HLA-DRB1—psoriasis	2.74e-05	0.000237	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CARM1—psoriasis	2.73e-05	0.000235	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.71e-05	0.000234	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—ICAM1—psoriasis	2.63e-05	0.000227	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NFKBIA—psoriasis	2.61e-05	0.000225	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2S1—psoriasis	2.59e-05	0.000224	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TNF—psoriasis	2.52e-05	0.000218	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SOCS1—psoriasis	2.46e-05	0.000212	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—PPARG—psoriasis	2.43e-05	0.00021	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.26e-05	0.000195	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—psoriasis	2.18e-05	0.000188	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—TYK2—psoriasis	2.14e-05	0.000185	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CARM1—psoriasis	2.1e-05	0.000182	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.06e-05	0.000178	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—IL6—psoriasis	2.03e-05	0.000176	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IFNG—psoriasis	2e-05	0.000173	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.97e-05	0.00017	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CARM1—psoriasis	1.94e-05	0.000167	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD4—psoriasis	1.94e-05	0.000167	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CARM1—psoriasis	1.92e-05	0.000166	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APOE—psoriasis	1.81e-05	0.000156	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—LEP—psoriasis	1.81e-05	0.000156	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—IL6—psoriasis	1.8e-05	0.000155	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.79e-05	0.000155	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAT—psoriasis	1.78e-05	0.000154	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HLA-A—psoriasis	1.77e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.76e-05	0.000152	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—JUN—psoriasis	1.73e-05	0.000149	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NFKBIA—psoriasis	1.69e-05	0.000146	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAT—psoriasis	1.68e-05	0.000145	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NFKB1—psoriasis	1.67e-05	0.000144	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APOE—psoriasis	1.65e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CARM1—psoriasis	1.64e-05	0.000141	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS2—psoriasis	1.54e-05	0.000133	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.53e-05	0.000132	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—STAT3—psoriasis	1.5e-05	0.000129	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—APOE—psoriasis	1.38e-05	0.000119	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TYK2—psoriasis	1.38e-05	0.000119	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—APOE—psoriasis	1.3e-05	0.000112	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAT—psoriasis	1.29e-05	0.000112	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CARM1—psoriasis	1.27e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TYK2—psoriasis	1.26e-05	0.000109	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—psoriasis	1.21e-05	0.000104	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—psoriasis	1.2e-05	0.000104	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAT—psoriasis	1.19e-05	0.000103	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAT—psoriasis	1.18e-05	0.000102	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CD4—psoriasis	1.14e-05	9.85e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—psoriasis	1.14e-05	9.8e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JUN—psoriasis	1.12e-05	9.66e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NFKB1—psoriasis	1.08e-05	9.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—psoriasis	1.05e-05	9.03e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAT—psoriasis	1.01e-05	8.7e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—APOE—psoriasis	1.01e-05	8.68e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—psoriasis	9.78e-06	8.44e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—psoriasis	9.69e-06	8.36e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—APOE—psoriasis	9.25e-06	7.98e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—APOE—psoriasis	9.17e-06	7.91e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—psoriasis	8.84e-06	7.62e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—psoriasis	8.76e-06	7.56e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—psoriasis	8.06e-06	6.95e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—psoriasis	7.99e-06	6.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—APOE—psoriasis	7.84e-06	6.76e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAT—psoriasis	7.78e-06	6.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—psoriasis	7.39e-06	6.38e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—psoriasis	6.83e-06	5.89e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—psoriasis	6.77e-06	5.84e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—psoriasis	6.17e-06	5.33e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—APOE—psoriasis	6.05e-06	5.22e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—psoriasis	5.27e-06	4.55e-05	CbGpPWpGaD
